|
US5591855A
(en)
|
1994-10-14 |
1997-01-07 |
Cephalon, Inc. |
Fused pyrrolocarbazoles
|
|
US5628984A
(en)
|
1995-07-31 |
1997-05-13 |
University Of North Carolina At Chapel Hill |
Method of detecting lung disease
|
|
EP0964864B1
(en)
|
1997-02-05 |
2008-04-09 |
Warner-Lambert Company LLC |
Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
|
|
GB9718913D0
(en)
|
1997-09-05 |
1997-11-12 |
Glaxo Group Ltd |
Substituted oxindole derivatives
|
|
US20040006074A1
(en)
|
1998-04-28 |
2004-01-08 |
The Government Of The United States Of America |
Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer
|
|
EP1086105B1
(en)
|
1998-06-16 |
2006-03-01 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Fused azepinone cyclin dependent kinase inhibitors
|
|
ATE380548T1
(de)
|
1999-01-29 |
2007-12-15 |
Univ Illinois |
Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
|
|
AU6314900A
(en)
|
1999-07-26 |
2001-02-13 |
Banyu Pharmaceutical Co., Ltd. |
Biarylurea derivatives
|
|
US6387900B1
(en)
|
1999-08-12 |
2002-05-14 |
Pharmacia & Upjohn S.P.A. |
3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
|
|
US6291504B1
(en)
|
1999-10-20 |
2001-09-18 |
Dupont Pharmaceuticals Company |
Acylsemicarbazides and their uses
|
|
US6867198B2
(en)
|
1999-12-16 |
2005-03-15 |
Eli Lilly And Company |
Agents and methods for the treatment of proliferative diseases
|
|
US7053070B2
(en)
|
2000-01-25 |
2006-05-30 |
Warner-Lambert Company |
Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
|
|
DK1686130T3
(da)
|
2000-06-26 |
2009-04-06 |
Pfizer Prod Inc |
Pyrrolo-[2,3-d]-pyrimidinforbindelser som immunsuppressive midler
|
|
ES2220811T3
(es)
|
2000-09-29 |
2004-12-16 |
Eli Lilly And Company |
Procedimiento y compuestos para el tratamiento de enfermedades proliferativas.
|
|
AU2002228692A1
(en)
|
2000-12-01 |
2002-06-11 |
Bristol-Myers Squibb Pharma Company |
3-(2,4-dimethylthiazol-5-yl) indeno(1,2-c)pyrazol-4-one derivatives as cdk inhibitors
|
|
DE60228692D1
(de)
|
2001-02-28 |
2008-10-16 |
Univ Temple |
Verwendung von alpha, beta ungesättigten arylsulfonen zum schutz von zellen und geweben vor toxizität ionischer strahlung
|
|
KR100863624B1
(ko)
*
|
2001-05-11 |
2008-10-15 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
Ｃｄ26을 발현하는 세포와 연관된 질환의 치료제로사용되는 항-ｃｄ26 단클론항체
|
|
MEP46108A
(en)
|
2002-01-22 |
2011-02-10 |
Warner Lambert Co |
2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
|
|
CA2495787A1
(en)
|
2002-05-01 |
2003-11-13 |
Chromos Molecular Systems, Inc. |
Methods for delivering nucleic acid molecules into cells and assessment thereof
|
|
EP1590341B1
(en)
|
2003-01-17 |
2009-06-17 |
Warner-Lambert Company LLC |
2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
|
|
BRPI0410563B8
(pt)
|
2003-05-22 |
2021-05-25 |
Nerviano Medical Sciences Srl |
compostos de pirazol-quinazolina, seus processos de preparação e composições farmacêuticas
|
|
PT1648889E
(pt)
|
2003-07-11 |
2008-12-10 |
Warner Lambert Co |
Sal isetionato de um inibidor selectivo da cdk4
|
|
CA2543308C
(en)
|
2003-10-23 |
2012-03-06 |
F. Hoffman-La Roche Ag |
Triaza-spiropiperidine derivatives for use as glyt-1 inhibitors in the treatment of neurological and neuropsychiatric disorders
|
|
GB0327380D0
(en)
|
2003-11-25 |
2003-12-31 |
Cyclacel Ltd |
Method
|
|
BRPI0509580A
(pt)
|
2004-03-30 |
2007-11-27 |
Pfizer Prod Inc |
combinações de inibidores de transdução de sinal
|
|
WO2005100999A2
(en)
|
2004-04-08 |
2005-10-27 |
Cornell Research Foundation, Inc. |
Functional immunohistochemical cell cycle analysis as a prognostic indicator for cancer
|
|
ITMI20040874A1
(it)
|
2004-04-30 |
2004-07-30 |
Ist Naz Stud Cura Dei Tumori |
Derivati indolici ed azaindolici con azione antitumorale
|
|
ES2411975T3
(es)
|
2005-01-14 |
2013-07-09 |
Janssen Pharmaceutica Nv |
Pirimidinas heterocíclicas anilladas de 5 miembros como inhibidores de cinasas
|
|
BRPI0606319A2
(pt)
|
2005-01-21 |
2009-06-16 |
Astex Therapeutics Ltd |
compostos farmacêuticos
|
|
EP2354139A1
(en)
|
2005-05-20 |
2011-08-10 |
Vertex Pharmaceuticals Incorporated |
Pyrrolopyridines useful as inhibitors of protein kinase
|
|
WO2007025090A2
(en)
|
2005-08-25 |
2007-03-01 |
Kalypsys, Inc. |
Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
|
|
EP1779848A1
(en)
|
2005-10-28 |
2007-05-02 |
Nikem Research S.R.L. |
V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
|
|
US7579351B2
(en)
|
2005-12-09 |
2009-08-25 |
Hoffmann-La Roche Inc. |
Tricyclic amide derivatives
|
|
JP2009524589A
(ja)
|
2005-12-22 |
2009-07-02 |
ワイス |
置換されたイソキノリン−１，３（２ｈ，４ｈ）−ジオン、１−チオキソ−１，４−ジヒドロ−２ｈ−イソキノリン−３−オン誘導体、および１，４−ジヒドロ−３（２ｈ）−イソキノロン、ならびにキナーゼインヒビターとしてのそれらの使用
|
|
CN101415409B
(zh)
|
2006-04-05 |
2012-12-05 |
诺瓦提斯公司 |
用于治疗癌症的治疗剂的组合
|
|
US20070270362A1
(en)
|
2006-05-18 |
2007-11-22 |
The University Of Washington |
Methods and compositions for prevention or treatment of inflammatory-related diseases and disorders
|
|
US8222256B2
(en)
|
2006-07-05 |
2012-07-17 |
Exelixis, Inc. |
Methods of using IGFIR and ABL kinase modulators
|
|
JP2010513317A
(ja)
|
2006-12-14 |
2010-04-30 |
パナシー ファーマシューティカルズ インコーポレーティッド |
サイクリン依存性キナーゼの阻害による神経保護方法
|
|
KR20090091306A
(ko)
|
2006-12-22 |
2009-08-27 |
노파르티스 아게 |
암, 염증 및 바이러스 감염 치료용 ｃｄｋ 억제제로서의 헤테로아릴-헤테로아릴 화합물
|
|
CA2690748A1
(en)
|
2007-06-25 |
2008-12-31 |
Neurogen Corporation |
Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
|
|
US9259399B2
(en)
|
2007-11-07 |
2016-02-16 |
Cornell University |
Targeting CDK4 and CDK6 in cancer therapy
|
|
WO2009085185A1
(en)
|
2007-12-19 |
2009-07-09 |
Amgen Inc. |
Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
|
|
JP5579715B2
(ja)
|
2008-07-29 |
2014-08-27 |
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ |
ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ
|
|
US8685980B2
(en)
|
2008-08-22 |
2014-04-01 |
Novartis Ag |
Pyrrolopyrimidine compounds and their uses
|
|
CA2738925A1
(en)
|
2008-10-01 |
2010-04-08 |
The University Of North Carolina At Chapel Hill |
Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
|
|
WO2010051127A2
(en)
|
2008-10-01 |
2010-05-06 |
The University Of North Carolina At Chapel Hill |
Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
|
|
PA8852901A1
(es)
|
2008-12-22 |
2010-07-27 |
Lilly Co Eli |
Inhibidores de proteina cinasa
|
|
WO2010132725A2
(en)
|
2009-05-13 |
2010-11-18 |
The University Of North Carolina At Chapel Hill |
Cyclin dependent kinase inhibitors and methods of use
|
|
US9040519B2
(en)
|
2010-02-18 |
2015-05-26 |
Medivation Technologies, Inc. |
Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
|
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
|
UY33226A
(es)
*
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
|
|
EP2632467B1
(en)
*
|
2010-10-25 |
2016-06-22 |
G1 Therapeutics, Inc. |
Cdk inhibitors
|
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
|
AU2011323455B2
(en)
|
2010-11-02 |
2017-07-27 |
Promega Corporation |
Coelenterazine derivatives and methods of using same
|
|
CN103501789A
(zh)
|
2010-11-17 |
2014-01-08 |
北卡罗来纳大学查珀尔希尔分校 |
通过抑制增殖性激酶cdk4和cdk6保护肾组织免于局部缺血
|
|
HUE024504T2
(en)
|
2010-12-23 |
2016-01-28 |
Sanofi Sa |
Pyrimidine derivatives, a process for their preparation and their use in medicine
|
|
WO2012129344A1
(en)
*
|
2011-03-23 |
2012-09-27 |
Amgen Inc. |
Fused tricyclic dual inhibitors of cdk 4/6 and flt3
|
|
BR112013033940A2
(pt)
|
2011-07-01 |
2017-02-14 |
Novartis Ag |
terapia combinada compreendendo um inibidor de cdk4/6 e um inibidor de pi3k para uso no tratamento de câncer
|
|
EP3216792B1
(en)
|
2012-03-29 |
2020-05-27 |
G1 Therapeutics, Inc. |
Lactam kinase inhibitors
|
|
CN104302620A
(zh)
|
2012-04-26 |
2015-01-21 |
弗朗西斯·泽维尔·塔瓦雷斯 |
内酰胺的合成
|
|
US9241941B2
(en)
|
2012-09-20 |
2016-01-26 |
Memorial Sloan-Kettering Cancer Center |
Methods for treatment of lymphomas with mutations in cell cycle genes
|
|
CN105407723A
(zh)
|
2013-03-15 |
2016-03-16 |
G1治疗公司 |
高效的抗赘生剂和抗增生剂
|
|
WO2014144847A2
(en)
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Hspc-sparing treatments for rb-positive abnormal cellular proliferation
|
|
US20140274896A1
(en)
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
|
|
BR112015025711A8
(pt)
|
2013-04-08 |
2019-12-17 |
Janssen Pharmaceutica Nv |
uso de ibrutinibe e coposição farmacêutica compreendendo ibrutinibe e um agente anticâncer
|
|
US20160257688A1
(en)
|
2013-10-24 |
2016-09-08 |
Francis Xavier Tavares |
Process for Synthesis of Lactams
|
|
US10314842B2
(en)
|
2013-12-02 |
2019-06-11 |
Cornell University |
Methods for treating B cell proliferative disorders
|
|
WO2015161285A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation
|
|
EP3191098A4
(en)
|
2014-09-12 |
2018-04-25 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
|
US20160220569A1
(en)
|
2015-02-03 |
2016-08-04 |
G1 Therapeutics, Inc. |
CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy
|